iBio appoints Molly Carr as CMO; grants 430,000 stock options at $1.40/share

iBio, Inc.

Dr. Carr appointed CMO effective July 31, 2026, leading global clinical strategy for obesity and cardiometabolic pipeline.
She previously served as Clinical Head at Eli Lilly, overseeing insulin/glucagon portfolio including Phase 3 efsitora.
Employment terms: $470,000 base salary, 40% target bonus, severance provisions.
Inducement award: options to purchase 430,000 shares at $1.40, vesting 25% after one year then monthly over 3 years.
Company advancing IBIO-600 and IBIO-610 into next clinical phases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.